CMS restricts coverage of Alzheimer’s drug Aduhelm to clinical trials
Apr 08, 2022
Coverage of aducanumab (Aduhelm) is officially limited to clinical trials only, the agency announced Thursday. Most stakeholders have called for restricted use while more efficacy and safety data is gathered,...
Biogen hit with class-action lawsuit involving Alzheimer’s drug Aduhelm
Feb 10, 2022
The lawsuit alleges securities fraud on behalf of investors, adding to the ongoing fallout following Aduhelm’s controversial approval and Medicare’s questionable coverage proposal.
Clinical briefs for Wednesday, Feb. 9
Feb 09, 2022
Higher pay not a cure-all for nurse retention, study shows … Majority of public support ongoing Aduhelm trials, would accept greater coverage costs, poll finds … 3G mobile network shutdown starts...
ARIA described from clinical trials of aducanumab for Alzheimer disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab
Ethical considerations explored for aducanumab in Alzheimer disease
Nov 19, 2021
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Clinical briefs for Thursday, Nov. 11
Nov 11, 2021
The next hospital crisis may be dementia behavioral emergencies, psychiatrist says … Neurologists prescribing Alzheimer’s drug Aduhelm talk about practices and payments … Patients with diabetes may...
Clinical briefs for Wednesday, Nov. 10
Nov 10, 2021
Legal challenges aside, senior living operators advised to prepare for COVID-19 vaccine mandate … Patient treated with Alzheimer’s drug aducanumab has six brain abnormality episodes … Feds invest...
Two-thirds of neurologists expect to start some patients on Aduhelm next year: survey
Sep 17, 2021
The outlook for the Alzheimer’s drug aducanumab (Aduhelm) is looking up, investigators say. There are small increases in the number of Aduhelm prescribers, and an uptick in patients for whom the...
Experts: More research needed before treating patients with controversial Alzheimer’s drug Aduhelm
Sep 13, 2021
The majority of patients with Alzheimer’s disease would not have been eligible to take part in the clinical trials of the new controversial Alzheimer’s drug aducanumab (Aduhelm), according...
U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...